Picture [LSA] – The Business Web Portal 650x89px
Document › Details

Evotec AG. (11/14/16). "Press Release: Evotec to Present at Two Upcoming IR Conferences in November". Hamburg.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
  Organisation 2 Deutsche Börse AG
  Today Deutsche Börse (Group)
  Group Deutsche Börse (Group)
Products Product Deutsches Eigenkapitalforum 2016 Frankfurt (German Equity Forum 2016)
  Product 2 drug discovery services
Index terms Index term Evotec–Deutsche Börse: investor conference, 201611 supply service Evotec AG presents at Deutsches Eigenkapitalforum 2016
  Index term 2 Evotec–Leucadia: investor conference, 201611 supply service Evotec AG presents at Jefferies 2016 Global Healthcare Conference London
Persons Person Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)
  Person 2 Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will present at the Jefferies 2016 Global Healthcare Conference in London, UK, and at the German Equity Forum 2016, Frankfurt, Germany.

Jefferies 2016 Global Healthcare Conference in London, UK
Date: Thursday, 17 November 2016, 04.00 pm GMT (05.00 pm CET)
Venue: London, UK
Presenter: Enno Spillner, Chief Financial Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation will be provided at

German Equity Forum 2016 in Frankfurt, Germany
Date: Tuesday, 22 November 2016, 10.00 am CET
Venue: Sheraton Frankfurt Airport Hotel and Conference Center, Frankfurt, Germany
Presenters: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG; Enno Spillner, Chief Financial Officer of Evotec AG


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:

Record changed: 2017-07-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top